Nevirapine/zidovudine/lamivudine has superior immunological and virological responses not reflected in clinical outcomes in a 48-week randomized comparison with abacavir/zidovudine/lamivudine in HIV-infected Ugandan adults with low CD4 cell counts

HIV Medicine

Volumn 11, Issue 5, 2010, Pages 334-344

  Munderi, P ^a   Walker, A S ^b   Kityo, C ^c   Babiker, A G ^b   Ssali, F ^c   Reid, A ^d   Darbyshire, J H ^b   Grosskurth, H ^a   Mugyenyi, P ^c   Gibb, D M ^b   Gilks, C F ^e  

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

^b MRC CLINICAL TRIALS UNIT   (United Kingdom)

^c JOINT CLINICAL RESEARCH CENTRE   (Uganda)

^d UNIVERSITY OF ZIMBABWE   (Zimbabwe)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Africa; Antiretroviral therapy; CD4; HIV; HIV 1 RNA; Randomized controlled trial

Indexed keywords

ABACAVIR; LAMIVUDINE PLUS ZIDOVUDINE; NEVIRAPINE; PLACEBO; STAVUDINE; TENOFOVIR; VIRUS RNA; ZIDOVUDINE; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ANEMIA; ARTICLE; BODY WEIGHT; CAUSE OF DEATH; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEPATITIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LIVER FAILURE; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEUTROPENIA; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UGANDA; VIRUS LOAD; BLOOD; DRUG COMBINATION; DRUG EFFECTS; HIV INFECTIONS; IMMUNOLOGY; MEDICATION COMPLIANCE; MIDDLE AGED; MULTICENTER STUDY; PROCEDURES; RECURRENT DISEASE; STANDARDS; VIROLOGY;

ADULT; BODY WEIGHT; CD4 LYMPHOCYTE COUNT; DIDEOXYNUCLEOSIDES; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LAMIVUDINE; MALE; MEDICATION ADHERENCE; MIDDLE AGED; NEVIRAPINE; RECURRENCE; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; TREATMENT OUTCOME; UGANDA; VIRAL LOAD; ZIDOVUDINE;

EID: 77953160346     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2009.00786.x     Document Type: Article

References (24)

1. Antiretroviral therapy for HIV infection in adults and adolescents in resource-limited settings: towards universal access. Recommendations for a public health approach 2006, World Health Organisation., In, WHO, Geneva
2. Gilks CF, Crowley S, Ekpini R. The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings. Lancet 2006, 368:505-510.
3. Gulick RM, Ribaudo HJ, Shikuma CM. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med 2004, 350:1850-1861.
4. DART Trial Team. Twenty-four-week safety and tolerability of nevirapine vs. abacavir in combination with zidovudine/lamivudine as first-line antiretroviral therapy: a randomized double-blind trial (NORA). Trop Med Int Health 2008, 13:6-16.
5. Ndembi N, Kaleebu P, Goodall RL. Dynamics of viral rebound and emergence of drug resistance in the absence of contemporaneous viral load testing: a randomised comparison between Combivir/Nevirapine and Combivir/Abacavir. J Infect Dis 2010, 201:106-113. on behalf of the DART Virology Group and Trial Team.
6. DART Trial Team. Fixed duration interruptions are inferior to continuous treatment in African adults starting therapy with CD4 cell counts <200 cells/microl. AIDS 2008, 22:237-247.
7. DART Trial team. Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial. 2009, DOI, 10.1016/S0140-6736(09)62067-5
8. Table for Grading Severity of Adult Adverse Experiences 1992, Division of AIDS., Bethesda, MD, National Institute of Allergy and Infectious Diseases
9. Amemiya T. Regression analysis when the dependent variable is truncated Normal. Econometrica 1973, 41:997-1016.
10. The Antiretroviral Therapy Cohort Collaboration. Rates of disease progression according to initial highly active antiretroviral therapy regimen: a collaborative analysis of 12 prospective cohort studies. J Infect Dis 2006, 194:612-622.
11. Mugavero MJ, May M, Harris R. Does short-term virologic failure translate to clinical events in antiretroviral-naive patients initiating antiretroviral therapy in clinical practice? AIDS 2008, 22:2481-2492.
12. Hughes MD. Initial treatment of HIV infection: randomized trials with clinical end points are still needed. J Infect Dis 2006, 194:542-544.
13. Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 1989, 8:431-440.
14. Fleming TR, DeMets DL. Surrogate end points in clinical trials: are we being misled? Ann Intern Med 1996, 125:605-613.
15. Human immunodeficiency virus type 1 RNA level and CD4 count as prognostic markers and surrogate end points: a meta-analysis. AIDS Res Hum Retroviruses 2000, 16:1123-1133. HIV Surrogate Marker Collaborative Group.
16. An evaluation of HIV RNA and CD4 cell count as surrogates for clinical outcome. AIDS 1999, 13:565-573. Delta Coordinating Committee and Virology Group.
17. Cameron DW, Heath-Chiozzi M, Danner S. Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group. Lancet 1998, 351:543-549.
18. Pozniak A. Surrogacy in HIV-1 clinical trials. Lancet 1998, 351:536-537.
19. Mills EJ, Kelly S, Bradley M, Mollon P, Cooper C, Nachega J. Antiretroviral effects on HIV-1 RNA, CD4 cell count and progression to AIDS or death: a meta-regression analysis. HIV Med 2008, 9:849-857.
20. Hirsch HH, Kaufmann G, Sendi P, Battegay M. Immune reconstitution in HIV-infected patients. Clin Infect Dis 2004, 38:1159-1166.
21. Battegay M, Nuesch R, Hirschel B, Kaufmann GR. Immunological recovery and antiretroviral therapy in HIV-1 infection. Lancet Infect Dis 2006, 6:280-287.
22. Lawn SD, Myer L, Bekker LG, Wood R. Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa. AIDS 2007, 21:335-341.
23. Palma P, Romiti ML, Cancrini C. Successful simplification of protease inhibitor-based HAART with triple nucleoside regimens in children vertically infected with HIV. AIDS 2007, 21:2465-2472.
24. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976, 16:31-41.